The rise of Corporate Venture Capital investment in UK biotech

This research quantifies the surge of corporate equity investing in UK biotech, as well as identifying the opportunity that as yet not even half of pharmaceutical industry CVCs are present or significantly active in the UK.

This report also sets out recommendations to grasp the potential opportunity at hand, to fulfil the ambition of making the UK a prime global biotech supercluster.